Clinical Trial

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

Study acronym: MOMENTUM-1
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Protocol Amendment History 4 changes
critical Trial status changed: Suspended → Active, Not Recruiting 2026-08-14
notable Enrollment reduced: 153 -> 4 participants 2026-08-14
critical Recruitment suspended 2026-05-23
notable Trial sites expanded: 3 -> 8 locations 2026-03-31
Trial Details
NCT Number NCT06955169
Lead Sponsor RTOG Foundation, Inc.
Collaborators: Novartis Pharmaceuticals
Conditions Intracranial Meningioma
Enrollment 4 participants
Start Date 2025-12-24
Primary Completion 2029-08 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-13